CSIMarket
 


Amneal Pharmaceuticals Inc   (AMRX)
Other Ticker:  
 
 

AMRX's Revenue Growth by Quarter and Year

Amneal Pharmaceuticals Inc 's Revenue results by quarter and year




AMRX Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 617.83 603.95 514.89 486.93
III Quarter September 619.53 544.23 527.91 463.90
II Quarter June 599.02 553.52 535.08 497.08
I Quarter March 557.19 497.57 493.11 383.61
FY   2,393.57 2,199.27 2,070.99 1,831.52



AMRX Revenue fourth quarter 2023 Y/Y Growth Comment
Amneal Pharmaceuticals Inc reported Revenue growth of 2.3% year on year in the fourth quarter 2023, to $ 617.83 millions, this is lower than Amneal Pharmaceuticals Inc 's recent average Revenue growth of 7.18%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 63 other companies have achieved higher Revenue growth. While Amneal Pharmaceuticals Inc ' s Revenue increase of 2.3% ranks overall at the positon no. 1162 in the fourth quarter 2023.




AMRX Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 2.3 % 17.3 % 5.74 % 51.15 %
III Quarter September 13.84 % 3.09 % 13.8 % 15.5 %
II Quarter June 8.22 % 3.45 % 7.64 % 26.54 %
I Quarter March 11.98 % 0.9 % 28.54 % -50.36 %
FY   8.83 % 6.19 % 13.07 % -3.06 %

Financial Statements
Amneal Pharmaceuticals Inc 's fourth quarter 2023 Revenue $ 617.83 millions AMRX's Income Statement
Amneal Pharmaceuticals Inc 's fourth quarter 2022 Revenue $ 603.95 millions Quarterly AMRX's Income Statement
New: More AMRX's historic Revenue Growth >>


AMRX Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -0.27 % 10.97 % -2.47 % 4.96 %
III Quarter September 3.42 % -1.68 % -1.34 % -6.67 %
II Quarter June 7.51 % 11.24 % 8.51 % 29.58 %
I Quarter March -7.74 % -3.36 % 1.27 % 19.08 %
FY (Year on Year)   8.83 % 6.19 % 13.07 % -3.06 %




Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #64
Healthcare Sector #182
Overall #1162

Revenue Y/Y Growth Statistics
High Average Low
29.38 % 7.18 % -21.95 %
(Mar 31 2021)   (Mar 31 2020)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #64
Healthcare Sector #182
Overall #1162
Revenue Y/Y Growth Statistics
High Average Low
29.38 % 7.18 % -21.95 %
(Mar 31 2021)   (Mar 31 2020)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Amneal Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
62.17 % 4.12 % -49.16 %
(Dec 31 2018)  


AMRX's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 Amneal Pharmaceuticals Inc reported decrease in Revenue sequentially by -0.27% to $ 617.83 millions, from $ 619.53 millions released a quarter before.

Even cyclical influence which commonly elevate IV. Quarter 2023 Revenue, this clearly has not been substantial to salvage Amneal Pharmaceuticals Inc 's IV. Quarter 2023 performance, Sierra Thompson, a business observer allocated in Boston pointed out.

Within Major Pharmaceutical Preparations industry 75 other companies have achieved higher Revenue quarter on quarter growth. While Amneal Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 1322.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #76
Healthcare Sector #217
Overall #1322
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #76
Healthcare Sector #217
Overall #1322
Revenue Q/Q Growth Statistics
High Average Low
62.17 % 4.12 % -49.16 %
(Dec 31 2018)  


AMRX's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 Amneal Pharmaceuticals Inc disclosed decrease in Revenue from the previous quarter by -0.27% to $ 617.83 millions, from $ 619.53 millions released in the previous reporting period.

Some cyclical circumstance could not recover the IV. Quarter for the Amneal Pharmaceuticals Inc , Sierra Thompson, a business observer allocated in Boston wrote, she voiced some pessimism conserning AMRX's outlook, she detected new challenges down the road for Amneal Pharmaceuticals Inc .

Within Major Pharmaceutical Preparations industry 75 other companies have achieved higher Revenue quarter on quarter growth. While Amneal Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 1322.


Amneal Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 2,393.57 $ 2,379.69 $ 2,304.39 $ 2,258.88 $ 2,199.27
Y / Y Revenue Growth (TTM) 8.83 % 12.77 % 10.05 % 8.84 % 6.19 %
Year on Year Revenue Growth Overall Ranking # 1054 # 1712 # 2488 # 1042 # 0
Seqeuential Revenue Change (TTM) 0.58 % 3.27 % 2.01 % 2.71 % 4.22 %
Seq. Revenue Growth (TTM) Overall Ranking # 1201 # 2143 # 2823 # 1782 # 0




Cumulative Revenue growth Comment
Assuming the Amneal Pharmaceuticals Inc 's fiscal year would have ended in Dec 31 2023, Amneal Pharmaceuticals Inc would have reprted above average annual Revenue improvement of 8.83% year on year, of $ 2,394 millions.
This marks a slow-down of the companys growth trends and from the 12.77% rise in Sep 30 2023.

In the Healthcare sector 168 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1054, from total ranking in previous quarter at 1712.

Revenue TTM Q/Q Growth Statistics
High Average Low
29.38 %
7.18 %
-21.95 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 67
Healthcare Sector # 169
Overall # 1054

Revenue TTM Y/Y Growth Statistics
High Average Low
29.38 %
7.18 %
-21.95 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 67
Sector # 190
S&P 500 # 1201
Cumulative Revenue growth Comment
Assuming the Amneal Pharmaceuticals Inc 's fiscal year would have ended in Dec 31 2023, Amneal Pharmaceuticals Inc would have reprted above average annual Revenue improvement of 8.83% year on year, of $ 2,394 millions.
This marks a slow-down of the companys growth trends and from the 12.77% rise in Sep 30 2023.

In the Healthcare sector 168 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1054, from total ranking in previous quarter at 1712.

Revenue TTM Q/Q Growth Statistics
High Average Low
29.38 %
7.18 %
-21.95 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 67
Healthcare Sector # 169
Overall # 1054

Revenue TTM Y/Y Growth Statistics
High Average Low
29.38 %
7.18 %
-21.95 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 67
Sector # 190
S&P 500 # 1201




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AMRX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for AMRX's Competitors
Revenue Growth for Amneal Pharmaceuticals Inc 's Suppliers
Revenue Growth for AMRX's Customers

You may also want to know
AMRX's Annual Growth Rates AMRX's Profitability Ratios AMRX's Asset Turnover Ratio AMRX's Dividend Growth
AMRX's Roe AMRX's Valuation Ratios AMRX's Financial Strength Ratios AMRX's Dividend Payout Ratio
AMRX's Roa AMRX's Inventory Turnover Ratio AMRX's Growth Rates AMRX's Dividend Comparisons



Companies with similar Revenue rise for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Surgery Partners Inc 4.00%$ 4.002 millions
Teladoc Health Inc 3.58%$ 3.578 millions
Iqvia Holdings Inc 3.45%$ 3.450 millions
Castle Biosciences Inc 3.39%$ 3.387 millions
Astrazeneca Plc3.29%$ 3.292 millions
West Pharmaceutical Services Inc 3.22%$ 3.217 millions
Becton Dickinson And Company2.62%$ 2.617 millions
Cumberland Pharmaceuticals Inc2.51%$ 2.514 millions
Prestige Consumer Healthcare Inc 2.33%$ 2.328 millions
Sanofi2.32%$ 2.324 millions
Amneal Pharmaceuticals Inc 2.30%$ 2.298 millions
Teleflex Incorporated2.09%$ 2.094 millions
Taro Pharmaceutical Industries Ltd2.07%$ 2.070 millions
Phibro Animal Health Corporation2.03%$ 2.032 millions
Icu Medical Inc1.94%$ 1.940 millions
Koninklijke Philips Nv1.92%$ 1.918 millions
Akebia Therapeutics Inc 1.84%$ 1.838 millions
Amedisys Inc 1.55%$ 1.552 millions
Abbott Laboratories1.49%$ 1.486 millions
Procyon Corporation1.36%$ 1.361 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com